Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,902,821

« Back to Dashboard

Summary for Patent: 5,902,821

Title: Use of carbazole compounds for the treatment of congestive heart failure
Abstract:A method of treatment using carvedilol is disclosed, wherein the carvedilol decreases the mortality caused by congestive heart failure in patients. The patients are titrated with low amounts of carvedilol, with the initial titration dosage being only 10 to 30% of the daily maintenance dose.
Inventor(s): Lukas-Laskey; Mary Ann (Rosemont, PA), Ruffolo, Jr.; Robert (Spring City, PA), Shusterman; Neil (Wynnewood, PA), Sponer; Gisbert (Laudenbach, DE), Strein; Klaus (Hemsbach, DE)
Assignee: Boehringer Mannheim Pharmaceuticals Corporation Smith Kline Corporation (Gaithersburg, MD)
Application Number:08/875,603
Patent Claim Types:
see list of patent claims
Use; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 3rd percentile
Forward Citations: 1st percentile

No matches for this query

Foreign Priority and PCT Information for Patent: 5,902,821

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany195 03 995Feb 08, 1995
PCT Information
PCT FiledFebruary 07, 1996PCT Application Number:PCT/EP96/00498
PCT Publication Date:August 15, 1996PCT Publication Number: WO96/24348

International Patent Family for Patent: 5,902,821

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China1185106► subscribe
China1093760► subscribe
Czech Republic9702463► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.